Immunosenescence and cancer

Journal of Geriatric Oncology

Volumn 1, Issue 1, 2010, Pages 20-26

  Pawelec, Graham ^a   Derhovanessian, Evelyna ^a   Larbi, Anis ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Chronic antigenic stress; Cytomegalovirus; Immune exhaustion; Immunosenescence

Indexed keywords

CANCER VACCINE; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN;

AGING; CANCER IMMUNIZATION; CANCER MODEL; CANCER RISK; CARCINOGENESIS; DRUG EFFICACY; HUMAN; HYPOXIA; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; IMMUNOSENESCENCE; IMMUNOSURVEILLANCE; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; STRESS; TUMOR IMMUNITY;

EID: 77953797875     PISSN: 18794068     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgo.2010.04.002     Document Type: Review

References (64)

1. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
2. Blankenstein T. Do autochthonous tumors interfere with effector T cell responses?. Semin Cancer Biol 2007, 17:267-274.
3. Prehn R.T., Prehn L.M. The flip side of immune surveillance: immune dependency. Immunol Rev 2008, 222:341-356.
4. Allavena P., Sica A., Solinas G., Porta C., Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008, 66:1-9.
5. Johansson M., Denardo D.G., Coussens L.M. Polarized immune responses differentially regulate cancer development. Immunol Rev 2008, 222:145-154.
6. Baldwin R.W. Immunity to methylcholanthrene-induced tumours in inbred rats following atrophy and regression of the implanted tumours. Br JCancer 1955, 9:652-657.
7. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
8. Blank C., Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007, 56:739-745.
9. Derhovanessian E., Solana R., Larbi A., Pawelec G. Immunity, ageing and cancer. Immun Ageing 2008, 5:11.
10. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059.
11. Wheeler C.J., Black K.L. DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin Investig Drugs 2009, 18:509-519.
12. McNeel D.G., Dunphy E.J., Davies J.G., Frye T.P., Johnson L.E., Staab M.J., et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009, 27:4047-4054.
13. Asemissen A.M., Brossart P. Vaccination strategies in patients with renal cell carcinoma. Cancer Immunol Immunother 2009, 58:1169-1174.
14. Derhovanessian E., Larbi A., Pawelec G. Biomarkers of human immunosenescence: impact of Cytomegalovirus infection. Curr Opin Immunol 2009, 21:440-445.
15. Grubeck-Loebenstein B., Della B.S., Iorio A.M., Michel J.P., Pawelec G., Solana R. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res 2009, 21:201-220.
16. Gottfried E., Kreutz M., Mackensen A. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev 2008, 19:65-77.
17. Hirokawa K., Utsuyama M., Ishikawa T., Kikuchi Y., Kitagawa M., Fujii Y., et al. Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells. Mech Ageing Dev 2009, 130:86-91.
18. Pawelec G., Derhovanessian E., Larbi A., Strindhall J., Wikby A. Cytomegalovirus and human immunosenescence. Rev Med Virol 2009, 19:47-56.
19. Dowd J.B., Aiello A.E., Alley D.E. Socioeconomic disparities in the seroprevalence of cytomegalovirus infection in the US population: NHANES III. Epidemiol Infect 2009, 137:58-65.
20. Looney R.J., Falsey A., Campbell D., Torres A., Kolassa J., Brower C., et al. Role of cytomegalovirus in the T cell changes seen in elderly individuals. Clin Immunol 1999, 90:213-219.
21. Chidrawar S., Khan N., Wei W., McLarnon A., Smith N., Nayak L., et al. Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals. Clin Exp Immunol 2009, 155:423-432.
22. Nizar S., Copier J., Meyer B., Bodman-Smith M., Galustian C., Kumar D., et al. T-regulatory cell modulation: the future of cancer immunotherapy?. Br J Cancer 2009, 100:1697-1703.
23. Gregg R., Smith C.M., Clark F.J., Dunnion D., Khan N., Chakraverty R., et al. The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age. Clin Exp Immunol 2005, 140:540-546.
24. Rosenkranz D., Weyer S., Tolosa E., Gaenslen A., Berg D., Leyhe T., et al. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol. 2007, 188:117-127.
25. Lages C.S., Suffia I., Velilla P.A., Huang B., Warshaw G., Hildeman D.A., et al. Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J Immunol 2008, 181:1835-1848.
26. Trzonkowski P., Szmit E., Mysliwska J., Mysliwski A. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans-impact of immunosenescence. Clin Immunol 2006, 119:307-316.
27. Hwang K.A., Kim H.R., Kang I. Aging and human CD4(+) regulatory T cells. Mech Ageing Dev 2009, 130:509-517.
28. Tsaknaridis L., Spencer L., Culbertson N., Hicks K., LaTocha D., Chou Y.K., et al. Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. J Neurosci Res 2003, 74:296-308.
29. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
30. Grizzle W.E., Xu X., Zhang S., Stockard C.R., Liu C., Yu S., et al. Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech Ageing Dev 2007, 128:672-680.
31. Hanson E.M., Clements V.K., Sinha P., Ilkovitch D., Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol 2009, 183:937-944.
32. Heithoff D.M., Enioutina E.Y., Bareyan D., Daynes R.A., Mahan M.J. Conditions that diminish myeloid-derived suppressor cell activities stimulate cross-protective immunity. Infect Immun 2008, 76:5191-5199.
33. Provinciali M. Immunosenescence and cancer vaccines. Cancer Immunol Immunother 2009, 58:1959-1967.
34. Pawelec G., Lustgarten J., Ruby C., Gravekamp C. Impact of aging on cancer immunity and immunotherapy. Cancer Immunol Immunother 2009, 58:1907-1908.
35. Shurin M.R., Shurin G.V., Chatta G.S. Aging and the dendritic cell system: implications for cancer. Crit Rev Oncol Hematol 2007, 64:90-105.
36. Grolleau-Julius A., Abernathy L., Harning E., Yung R.L. Mechanisms of murine dendritic cell antitumor dysfunction in aging. Cancer Immunol Immunother 2009, 58:1935-1939.
37. Croft M., So T., Duan W., Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 2009, 229:173-191.
38. Ruby C.E., Weinberg A.D. The effect of aging on OX40 agonist-mediated cancer immunotherapy. Cancer Immunol Immunother 2009, 58:1941-1947.
39. Tang Y.C., Thoman M., Linton P.J., Deisseroth A. Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged. Cancer Immunol Immunother 2009, 58:1949-1957.
40. Lustgarten J. Cancer, aging and immunotherapy: lessons learned from animal models. Cancer Immunol Immunother 2009, 58:1979-1989.
41. Pawelec G., Rehbein A., Haehnel K., Merl A., Adibzadeh M. Human T-cell clones in long-term culture as a model of immunosenescence. Immunol Rev 1997, 160:31-42.
42. Maini M.K., Gudgeon N., Wedderburn L.R., Rickinson A.B., Beverley P.C. Clonal expansions in acute EBV infection are detectable in the CD8 and not the CD4 subset and persist with a variable CD45 phenotype. J Immunol 2000, 165:5729-5737.
43. Plunkett F.J., Soares M.V., Annels N., Hislop A., Ivory K., Lowdell M., et al. The flow cytometric analysis of telomere length in antigen-specific CD8+ T cells during acute Epstein-Barr virus infection. Blood 2001, 97:700-707.
44. Hadrup S.R., Strindhall J., Kollgaard T., Seremet T., Johansson B., Pawelec G., et al. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol 2006, 176:2645-2653.
45. Mazzatti D.J., White A., Forsey R.J., Powell J.R., Pawelec G. Gene expression changes in long-term culture of T-cell clones: genomic effects of chronic antigenic stress in aging and immunosenescence. Aging Cell 2007, 6:155-163.
46. Mazzatti D.J., Pawelec G., Longdin R., Powell J.R., Forsey R.J. SELDI-TOF-MS ProteinChip array profiling of T-cell clones propagated in long-term culture identifies human profilin-1 as a potential bio-marker of immunosenescence. Proteome Sci 2007, 5:7.
47. Walter S., Bioley G., Buhring H.J., Koch S., Wernet D., Zippelius A., et al. High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. Eur J Immunol 2005, 35:2876-2885.
48. Sebastian Attig, Jörg Hennenlotter, Graham Pawelec, Gerd Klein, Sven Koch, Hanspeter Pircher, et al. under revision. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 2009, 69:8412-8419.
49. Yip W.K., Abdullah M.A., Yusoff S.M., Seow H.F. Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients. Clin Exp Immunol 2009, 155:412-422.
50. Ai W.Z., Hou J.Z., Zeiser R., Czerwinski D., Negrin R.S., Levy R. Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. Int J Cancer 2009, 124:239-244.
51. Moo-Young T.A., Larson J.W., Belt B.A., Tan M.C., Hawkins W.G., Eberlein T.J., et al. Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother 2009, 32:12-21.
52. Piersma S.J., Welters M.J., van der Burg S.H. Tumor-specific regulatory T cells in cancer patients. Hum Immunol 2008, 69:241-249.
53. Muenst S., Hoeller S., Dirnhofer S., Tzankov A. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol 2009, 40:1715-1722.
54. Carreras J., Lopez-Guillermo A., Roncador G., Villamor N., Colomo L., Martinez A., et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 2009, 27:1470-1476.
55. Dejaco C., Duftner C., Schirmer M. Are regulatory T-cells linked with aging?. Exp Gerontol 2006, 41:339-345.
56. Ben-Shoshan J., Maysel-Auslender S., Mor A., Keren G., George J. Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur. J Immunol 2008, 38:2412-2418.
57. Chen I.H., Lai Y.L., Wu C.L., Chang Y.F., Chu C.C., Tsai I.F., et al. Immune impairment in patients with terminal cancers: influence of cancer treatments and cytomegalovirus infection. Cancer Immunol Immunother Aug 15 2009, [Electronic publication ahead of print].
58. Derhovanessian E. Impact of Cytomegalovirus infection on immune signatures in cancer patients. Cancer Immunol Immunother Sep 15 2009, [Electronic publication ahead of print].
59. Herne K.L., Talpur R., Breuer-McHam J., Champlin R., Duvic M. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome. Blood 2003, 101:2132-2136.
60. Gupta R.K., Ramble J., Tong C.Y., Whittaker S., MacMahon E. Cytomegalovirus seroprevalence is not higher in patients with mycosis fungoides/Sezary syndrome. Blood 2006, 107:1241-1242.
61. Broccolo F., Cassina G., Chiari S., Garcia-Parra R., Villa A., Leone B.E., et al. Frequency and clinical significance of human beta-herpesviruses in cervical samples from Italian women. J Med Virol 2008, 80:147-153.
62. Chan P.K., Chan M.Y., Li W.W., Chan D.P., Cheung J.L., Cheng A.F. Association of human beta-herpesviruses with the development of cervical cancer: bystanders or cofactors. J Clin Pathol 2001, 54:48-53.
63. Tsai J.H., Hsu C.S., Tsai C.H., Su J.M., Liu Y.T., Cheng M.H., et al. Relationship between viral factors, axillary lymph node status and survival in breast cancer. J Cancer Res Clin Oncol 2007, 133:13-21.
64. Richardson A.K., Cox B., McCredie M.R., Dite G.S., Chang J.H., Gertig D.M., et al. Cytomegalovirus, Epstein-Barr virus and risk of breast cancer before age 40 years: a case-control study. Br Cancer 2004, 90:2149-2152.